Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Thompson AM, et al. Among authors: ashcroft l. Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1. Breast Cancer Res Treat. 2011. PMID: 20809362
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG. Howell A, et al. Among authors: ashcroft l. Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29097444 Clinical Trial.
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: ashcroft l. Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246. Clin Cancer Res. 2006. PMID: 17145825
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: ashcroft l. Clin Cancer Res. 2006 Dec 1;12(23):7025-32. doi: 10.1158/1078-0432.CCR-06-1244. Clin Cancer Res. 2006. PMID: 17145824
Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer.
Bundred NJ, Stockton C, Keeley V, Riches K, Ashcroft L, Evans A, Skene A, Purushotham A, Bramley M, Hodgkiss T; Investigators of BEA/PLACE studies. Bundred NJ, et al. Among authors: ashcroft l. Breast Cancer Res Treat. 2015 May;151(1):121-9. doi: 10.1007/s10549-015-3357-8. Epub 2015 Apr 8. Breast Cancer Res Treat. 2015. PMID: 25850535 Clinical Trial.
45 results